PADIMAC研究中新诊断患者的RNA测序产生硼替佐米/来那度胺决策特征
研究对PADIMAC二期试验中新诊断多发性骨髓瘤患者样本行RNA测序,开发并训练7基因特征预测治疗结局,并在硼替佐米和来那度胺为基础治疗的独立队列中验证。该特征能区分患者对哪种方案反应更好。在CoMMpass数据集中,按特征正确治疗的患者无进展生存和总生存优于未正确治疗者,且不劣于硼替佐米、来那度胺和地塞米松联合治疗。
要点
- 基于RNA测序开发7基因特征,可预测多发性骨髓瘤患者对硼替佐米或来那度胺方案的应答差异。
- CoMMpass中按特征正确治疗者无进展生存优于未正确治疗者(中位20.1个月 vs 未达到;HR 0.40)。
- CoMMpass中按特征正确治疗者总生存优于未正确治疗者(中位30.7个月 vs 未达到;HR 0.41)。
核心结论
- 7基因特征能区分新诊断多发性骨髓瘤患者对硼替佐米为基础或来那度胺为基础方案哪种应答更好。
- 在CoMMpass数据集中,按特征正确治疗者的无进展生存和总生存优于未正确治疗者,且不劣于硼替佐米、来那度胺和地塞米松联合治疗。
- 特征较小有利于临床转化,从而在多发性骨髓瘤中实现更有针对性的药物治疗方案。
研究设计与样本
- 对PADIMAC二期研究(硼替佐米、阿霉素和地塞米松治疗初治多发性骨髓瘤:延迟自体干细胞移植患者微小残留病的影响)中新诊断患者的样本行RNA测序。
- 使用合成退火和大间隔最近邻算法开发并训练7基因特征以预测治疗结局。
- 在接受硼替佐米为基础和来那度胺为基础治疗的独立队列中测试该特征。
主要发现
- 该特征能区分哪些患者对哪种方案应答更好。
- 在CoMMpass数据集中,按特征正确治疗的患者无进展生存优于未正确治疗者(中位20.1个月 vs 未达到;HR 0.40;CI 0.23-0.72;P = .0012)。
- 在CoMMpass数据集中,按特征正确治疗的患者总生存优于未正确治疗者(中位30.7个月 vs 未达到;HR 0.41;CI 0.21-0.80;P = .0049)。
- 按特征正确治疗者的结局不劣于接受硼替佐米、来那度胺和地塞米松联合治疗者,后者在美国可视为标准治疗但其他地方未广泛可用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improving outcomes in multiple myeloma will involve not only development of new therapies but also better use of existing treatments. We performed RNA sequencing on samples from newly diagnosed patients enrolled in the phase 2 PADIMAC (Bortezomib, Adriamycin, and Dexamethasone Therapy for Previously Untreated Patients with Multiple Myeloma: Impact of Minimal Residual Disease in Patients with Deferred ASCT) study. Using synthetic annealing and the large margin nearest neighbor algorithm, we developed and trained a 7-gene signature to predict treatment outcome. We tested the signature in independent cohorts treated with bortezomib- and lenalidomide-based therapies. The signature was capable of distinguishing which patients would respond better to which regimen. In the CoMMpass data set, patients who were treated correctly according to the signature had a better progression-free survival (median, 20.1 months vs not reached; hazard ratio [HR], 0.40; confidence interval [CI], 0.23-0.72; P = .0012) and overall survival (median, 30.7 months vs not reached; HR, 0.41; CI, 0.21-0.80; P = .0049) than those who were not. Indeed, the outcome for these correctly treated patients was noninferior to that for those treated with combined bortezomib, lenalidomide, and dexamethasone, arguably the standard of care in the United States but not widely available elsewhere. The small size of the signature will facilitate clinical translation, thus enabling more targeted drug regimens to be delivered in myeloma.
引用
- Chapman MA, Sive J, Ambrose J, et al. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature. Blood. 2018. PMID: 30181174. doi:10.1182/blood-2018-05-849893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。